摘要
目的探讨贝伐珠单抗联合化疗方案对肺腺癌患者中性粒细胞与淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)、血小板与淋巴细胞比值(platelet-to-lymphocyte ratio,PLR)、中性粒细胞与淋巴细胞比值(utrophil-to-lymphocyte ratio,NWR)、淋巴细胞与白细胞总数比值(lymphocyte-to-white blood cell ratio,LWR)及淋巴细胞亚群影响。方法选择2022年3月至2024年3月于亳州宝璋医院接受治疗的肺腺癌患者102例,随机分为研究组和对照组,每组51例。两组均予程序性死亡受体1抑制剂^(+)培美曲塞^(+)铂类治疗,研究组加予贝伐珠单抗。比较两组治疗后疗效、血常规、淋巴细胞亚群、Karnofsky功能状态评分标准(Karnofsky performance status,KPS)评分及不良反应发生情况。结果治疗后,研究组总有效率高于对照组(82.35%vs.60.78%,P<0.05)。两组NLR、PLR、NWR、LWR水平较前均降低,且研究组低于对照组(P<0.05)。两组自然杀伤细胞、白细胞分化抗原(cluster of differentiation,CD)4^(+)/CD8^(+)水平较前均升高,且研究组高于对照组(P<0.05)。研究组KPS评分高于对照组[(89.91±6.62)分vs.(83.44±8.93)分,P<0.05]。两组不良反应发生率差异无统计学意义(P>0.05)。结论贝伐珠单抗辅助治疗肺腺癌可帮助增强疗效,改善患者NLR、PLR、NWR、LWR及淋巴细胞亚群水平,且不增加不良反应。
Objective To investigate the effects of bevacizumab combined with chemotherapy regimen on neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),utrophil-to-lymphocyte ratio(NWR),lymphocyte-to-white blood cell ratio(LWR)and lymphocyte subpopulations in patients with lung adenocarcinoma.Methods A total of 102 patients with lung adenocarcinoma who received treatment in Baozhang Hospital from March 2022 to March 2024 were randomly divided into study group and control group,with 51 cases in each group.Both groups were treated with programmed death receptor 1 inhibitor+pemetrexed+platinum,while the study group was additionally treated with bevacizumab.The therapeutic efficacy,blood routine,lymphocyte subsets,Karnofsky performance status(KPS)score and the occurrence of adverse reactions were compared between the two groups after treatment.Results After treatment,the total effective rate of the study group was higher than that of the control group(82.35%vs.60.78%,P<0.05).The levels of NLR,PLR,NWR and LWR in both groups were decreased compared with those before treatment,and the study group was lower than the control group(P<0.05).The levels of natural killer cells and cluster of differentiation(CD)4^(+)/CD8^(+)in both groups were increased compared with those before treatment,and the study group was higher than the control group(P<0.05).The KPS score of the study group was higher than that of the control group[(89.91±6.62)points vs.(83.44±8.93)points,P<0.05].There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Bevacizumab as an adjuvant therapy for lung adenocarcinoma can enhance the efficacy,improve the levels of NLR,PLR,NWR,LWR and lymphocyte subpopulations in patients,and does not increase the occurrence of adverse reactions.
作者
应乐
陶玉
杨宏博
宋楠
杨玉柱
YING Le;TAO Yu;YANG Hongbo;SONG Nan;YANG Yuzhu(Department of Oncology,Baozhang Hospital,Bozhou Anhui,Bozhou 236705,Anhui Province,China;Department of Oncology,Lu'an People's Hospital of Anhui Province,Lu'an 237000,Anhui Province,China)
出处
《世界临床药物》
2025年第3期271-276,共6页
World Clinical Drug
作者简介
应乐,硕士,主治医师,研究方向:肿瘤内科疾病诊治;通信作者:杨玉柱,副主任医师,研究方向:肿瘤内科疾病诊治。
